These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1698 related articles for article (PubMed ID: 22722830)

  • 1. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
    Misale S; Yaeger R; Hobor S; Scala E; Janakiraman M; Liska D; Valtorta E; Schiavo R; Buscarino M; Siravegna G; Bencardino K; Cercek A; Chen CT; Veronese S; Zanon C; Sartore-Bianchi A; Gambacorta M; Gallicchio M; Vakiani E; Boscaro V; Medico E; Weiser M; Siena S; Di Nicolantonio F; Solit D; Bardelli A
    Nature; 2012 Jun; 486(7404):532-6. PubMed ID: 22722830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.
    Diaz LA; Williams RT; Wu J; Kinde I; Hecht JR; Berlin J; Allen B; Bozic I; Reiter JG; Nowak MA; Kinzler KW; Oliner KS; Vogelstein B
    Nature; 2012 Jun; 486(7404):537-40. PubMed ID: 22722843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
    Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab.
    Wadlow RC; Hezel AF; Abrams TA; Blaszkowsky LS; Fuchs CS; Kulke MH; Kwak EL; Meyerhardt JA; Ryan DP; Szymonifka J; Wolpin BM; Zhu AX; Clark JW
    Oncologist; 2012; 17(1):14. PubMed ID: 22210091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines.
    Messner I; Cadeddu G; Huckenbeck W; Knowles HJ; Gabbert HE; Baldus SE; Schaefer KL
    J Cancer Res Clin Oncol; 2013 Feb; 139(2):201-9. PubMed ID: 23015072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
    Siena S; Sartore-Bianchi A; Di Nicolantonio F; Balfour J; Bardelli A
    J Natl Cancer Inst; 2009 Oct; 101(19):1308-24. PubMed ID: 19738166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors.
    Mancl EE; Kolesar JM; Vermeulen LC
    Am J Health Syst Pharm; 2009 Dec; 66(23):2105-12. PubMed ID: 19923311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.
    Sorich MJ; Wiese MD; Rowland A; Kichenadasse G; McKinnon RA; Karapetis CS
    Ann Oncol; 2015 Jan; 26(1):13-21. PubMed ID: 25115304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.
    Sood A; McClain D; Maitra R; Basu-Mallick A; Seetharam R; Kaubisch A; Rajdev L; Mariadason JM; Tanaka K; Goel S
    Clin Colorectal Cancer; 2012 Jun; 11(2):143-50. PubMed ID: 22285706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    Mao C; Yang ZY; Hu XF; Chen Q; Tang JL
    Ann Oncol; 2012 Jun; 23(6):1518-25. PubMed ID: 22039088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
    Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
    Ruzzo A; Graziano F; Canestrari E; Magnani M
    Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
    De Roock W; Jonker DJ; Di Nicolantonio F; Sartore-Bianchi A; Tu D; Siena S; Lamba S; Arena S; Frattini M; Piessevaux H; Van Cutsem E; O'Callaghan CJ; Khambata-Ford S; Zalcberg JR; Simes J; Karapetis CS; Bardelli A; Tejpar S
    JAMA; 2010 Oct; 304(16):1812-20. PubMed ID: 20978259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies.
    Esposito C; Rachiglio AM; La Porta ML; Sacco A; Roma C; Iannaccone A; Tatangelo F; Forgione L; Pasquale R; Barbaro A; Botti G; Ciardiello F; Normanno N
    Cancer Biol Ther; 2013 Dec; 14(12):1143-6. PubMed ID: 24025416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients.
    Cappuzzo F; Varella-Garcia M; Finocchiaro G; Skokan M; Gajapathy S; Carnaghi C; Rimassa L; Rossi E; Ligorio C; Di Tommaso L; Holmes AJ; Toschi L; Tallini G; Destro A; Roncalli M; Santoro A; Jänne PA
    Br J Cancer; 2008 Jul; 99(1):83-9. PubMed ID: 18577988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.
    Heinemann V; Stintzing S; Kirchner T; Boeck S; Jung A
    Cancer Treat Rev; 2009 May; 35(3):262-71. PubMed ID: 19117687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
    Montagut C; Iglesias M; Arumi M; Bellosillo B; Gallen M; Martinez-Fernandez A; Martinez-Aviles L; Cañadas I; Dalmases A; Moragon E; Lema L; Serrano S; Rovira A; Rojo F; Bellmunt J; Albanell J
    Br J Cancer; 2010 Mar; 102(7):1137-44. PubMed ID: 20234366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
    J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 85.